Novartis Pharma AG: Novartis PluvictoTM shows statistically significant and clinically meaningful radiographic progression-free survival benefit in patients with PSMA-positive metastatic castration-resistant prostate cancer

Ad hoc announcement pursuant to Art. 53 LR Phase III PSMAfore trial with PluvictoTM met the primary endpoint of radiographic progression-free survival (rPFS) in PSMA-positive mCRPC who have been treated

Related Keywords

United States ,New Jersey ,United Kingdom ,Indiana ,Millburn ,Highland ,Canada ,Switzerland ,Crawford ,South Lanarkshire ,America ,Canadian ,Great Britain ,American ,Shreeram Aradhye ,Richard Jarvis ,Isabella Zinck ,Michael Meo ,Satoshi Sugimoto ,Nicole Zinsli Somm ,Samir Shah ,Parag Mahanti ,Julie Masow ,Sloan Simpson ,Mary Carmichael ,Twitter ,Elsevier Inc ,International Prospective ,Novartis ,Us National Library Of Medicine ,Novartis Pharmaceuticals ,Committee For Medicinal Products Human Use ,American Cancer Society ,Accelerator Applications United States Inc ,Drug Administration ,Regulatory Agency ,Exchange Commission ,Global Drug Development ,European Medicines Agency ,Health Canada ,Chief Medical Officer ,United States Food ,Medicinal Products ,Human Use ,Prostate Cancer ,Radioligand Therapy ,Phenotypic Precision Medicine ,Advanced Prostate ,Metastatic Castration Resistant Prostate ,Survival Rates ,Metastatic Prostate ,Radiographic Progression Free Survival ,Sequential Treatment Using Abiraterone ,Propensity Score Matched Analysis ,Advanced Accelerator Applications United States ,Accelerator Applications United States ,Receptor Directed Therapy ,Combination With Soc ,Versus Soc Alone ,Adult Male Patients With ,Clinical Radiation ,Nucl Med ,Dharma ,Pluvicto ,Shows ,Statistically ,Significant ,Linically ,Meaningful ,Radiographic ,Progression ,Tree ,Survival ,Benefit ,Patients ,Visma ,Positive ,Metastatic ,Castration ,Resistant ,Prostate ,